

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 July 2025 (10.07.2025)



(10) International Publication Number
WO 2025/147555 A1

(51) International Patent Classification:

A61K 31/4184 (2006.01) A61K 31/519 (2006.01)
A61K 31/445 (2006.01) A61K 45/06 (2006.01)
A61K 31/4523 (2006.01) A61P 35/00 (2006.01)
A61K 31/517 (2006.01)

(21) International Application Number:

PCT/US2025/010152

(22) International Filing Date:

03 January 2025 (03.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/617,818 05 January 2024 (05.01.2024) US

(71) Applicant: **RECURSION PHARMACEUTICALS, INC.** [US/US]; 41 S. Rio Grande Street, Salt Lake City, UT 84101 (US).

(72) Inventors: **TOUTOUNCHIAN, Jordan**; 41 S. Rio Grande Street, Salt Lake City, UT 84101 (US). **ROWLEY, Shane**; 41 S. Rio Grande Street, Salt Lake City, UT 84101 (US).

ANDERSON, Daniel, James; 41 S. Rio Grande Street, Salt Lake City, UT 84101 (US). **GUTHRIE, Matthew**; 41 S. Rio Grande Street, Salt Lake City, UT 84101 (US). **LEVIN, Rebecca**; 41 S. Rio Grande Street, Salt Lake City, UT 84101 (US). **ALFA, Ronald, Wakim**; 41 S. Rio Grande Street, Salt Lake City, UT 84101 (US).

(74) Agent: **DANEK, Shelley, C.** et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: REC-4881 (TAK-733) FOR USE IN TREATING OR PREVENTING COLORECTAL CANCER AND RELATED DISEASES




FIG. 1

(57) Abstract: Methods are provided for treating or preventing colorectal cancer, related diseases, or symptoms of any of the foregoing, e.g., familial adenomatous polyposis (FAP), in subjects of 55 years or older. The methods include administering 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4, 7-dione or a pharmaceutically acceptable salt thereof.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))